On July 1, Guardant Health rose 5.35% in pre-market trading, trading near $158.05/share with turnover of approximately $672,000. The rally was driven by a bullish initiation from Bernstein.

Bernstein issued an Outperform rating on the company with a $175 price target, highlighting that G360 ADLT pricing qualification is expected to unlock meaningful revenue upside not yet reflected in consensus estimates. The firm's earnings projections stand 6.6% above consensus for fiscal year 2027 and 12.2% above for 2028. Bernstein also noted that the market significantly underestimates the company's gross margin improvement potential, with the transition to the NovaSeq X platform expected to contribute 350 to 550 basis points of positive impact over the full year.

The upgrade follows a series of positive catalysts in recent months, including FDA approvals for Guardant360 CDx and Guardant360 Liquid CDx as companion diagnostics, inclusion of the Shield blood test in American Cancer Society screening guidelines, and a Q1 earnings beat with revenue guidance raised to $1.30B-$1.32B versus the $1.27B FactSet estimate.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)